Cerebrospinal fluid levels of Alzheimer’s disease biomarkers in middle-aged patients with type 1 diabetes

Diabetologia

Volumn 57, Issue 10, 2014, Pages 2208-2214

  Ouwens, D Margriet ^a,b   van Duinkerken, Eelco ^c   Schoonenboom, S Niki M ^c   Herzfeld de Wiza, Daniella ^a   Klein, Martin ^c   van Golen, Larissa ^c   Pouwels, Petra J W ^c   Barkhof, Frederik ^c   Moll, Annette C ^c   Snoek, Frank J ^c   Teunissen, Charlotte E ^c   Scheltens, Philip ^c   Diamant, Michaela ^c  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer s disease; Cognitive function; Tau; Type 1 diabetes; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; COLONY STIMULATING FACTOR 1; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); LRP1 PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTELLIGENCE QUOTIENT; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RISK; WHITE MATTER; GENOTYPE; METABOLISM;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; GENOTYPE; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MACROPHAGE COLONY-STIMULATING FACTOR; MIDDLE AGED; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84935468213     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3333-6     Document Type: Article

References (26)

1. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64–74
2. Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP (2005) The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 28:726–735
3. van Duinkerken E, Klein M, Schoonenboom NS et al (2009) Functional brain connectivity and neurocognitive functioning in patients with long-standing type 1 diabetes with and without microvascular complications: a magnetoencephalography study. Diabetes 58:2335–2343
4. van Duinkerken E, Schoonheim MM, Ijzerman RG et al (2012) Diffusion tensor imaging in type 1 diabetes: decreased white matter integrity relates to cognitive functions. Diabetologia 55:1218–1220
5. van Duinkerken E, Schoonheim MM, Sanz-Arigita EJ et al (2012) Resting-state brain networks in type 1 diabetic patients with and without microangiopathy and their relation to cognitive functions and disease variables. Diabetes 61:1814–1821
6. Sims-Robinson C, Kim B, Rosko A, Feldman EL (2010) How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6:551–559
7. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2:605–613
8. Bell RD (2012) The imbalance of vascular molecules in Alzheimer’s disease. J Alzheimers Dis 32:699–709
9. Du Yan S, Zhu H, Fu J et al (1997) Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A 94:5296–5301
10. Bouwman FH, Schoonenboom SN, van der Flier WM et al (2007) CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 28:1070–1074
11. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228–234
12. Kester MI, van der Flier WM, Mandic G, Blankenstein MA, Scheltens P, Muller M (2010) Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer’s disease. J Alzheimers Dis 20:1083–1090
13. de Jong D, Jansen RW, Kremer BP, Verbeek MM (2006) Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. J Gerontol A Biol Sci Med Sci 61:755–758
14. Mattsson N, Zetterberg H, Hansson O et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385–393
15. Mulder C, Verwey NA, van der Flier WM et al (2010) Amyloid-beta(1–42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56:248–253
16. Watson GS, Peskind ER, Asthana S et al (2003) Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60:1899–1903
17. Kim B, Backus C, Oh S, Hayes JM, Feldman EL (2009) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150:5294–5301
18. Liu F, Shi J, Tanimukai H et al (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease. Brain 132:1820–1832
19. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets 8:16–30
20. Deane R, Du Yan S, Submamaryan RK et al (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9:907–913
21. Sagare A, Deane R, Bell RD et al (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13:1029–1031
22. Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV (2011) Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-beta is an early biomarker for mild cognitive impairment preceding Alzheimer’s disease. J Alzheimers Dis 24:25–34
23. Jaeger LB, Dohgu S, Hwang MC et al (2009) Testing the neurovascular hypothesis of Alzheimer’s disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis 17:553–570
24. Shi YM, Zhou H, Zhang ZJ et al (2009) Association of the LRP1 gene and cognitive performance with amnestic mild cognitive impairment in elderly Chinese. Int Psychogeriatr 21:1072–1080
25. Li G, Millard SP, Peskind ER et al (2014) Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. JAMA Neurol 71:742–751
26. Heine RJ, Yki-Jarvinen H, Kahn SE, van Raalte DH (2014) In Memoriam: Michaela Diamant, 11 April 1962–9 April 2014. Diabetologia 57:1271